VEGF


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
02 2019
Historique:
received: 15 11 2017
accepted: 29 07 2018
revised: 25 06 2018
pubmed: 9 9 2018
medline: 27 2 2019
entrez: 9 9 2018
Statut: ppublish

Résumé

Vascular endothelial growth factor-A (VEGF-A) is highly subjected to alternative pre-mRNA splicing that generates several splice variants. The VEGF

Identifiants

pubmed: 30194450
doi: 10.1038/s41388-018-0486-7
pii: 10.1038/s41388-018-0486-7
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Integrin beta1 0
Neoplasm Proteins 0
Protein Isoforms 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
Bevacizumab 2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1050-1066

Commentaires et corrections

Type : ErratumIn

Références

Br J Cancer. 2008 Apr 8;98(7):1250-7
pubmed: 18349828
PLoS One. 2012;7(10):e46539
pubmed: 23071587
Cancer Res. 2004 Nov 1;64(21):7822-35
pubmed: 15520188
Cell Death Differ. 2006 Feb;13(2):260-72
pubmed: 16052233
Lung Cancer. 2014 Feb;83(2):182-8
pubmed: 24388706
J Clin Oncol. 2013 Mar 20;31(9):1219-30
pubmed: 23401453
J Pathol. 2003 Jul;200(3):336-47
pubmed: 12845630
Br J Cancer. 2008 Apr 22;98(8):1366-79
pubmed: 18349829
Oncogene. 2003 Mar 27;22(12):1822-35
pubmed: 12660818
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Cancer Res. 2008 Jun 15;68(12):4683-92
pubmed: 18559514
Nat Rev Cancer. 2013 Dec;13(12):871-82
pubmed: 24263190
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Cell Death Differ. 2008 Dec;15(12):1815-23
pubmed: 18806759
Mol Cancer. 2010 Dec 31;9:320
pubmed: 21194429
Cancer Res. 2002 Dec 15;62(24):7203-6
pubmed: 12499259
Eur J Cancer. 2008 Sep;44(13):1883-94
pubmed: 18657413
Methods Mol Biol. 2012;878:121-35
pubmed: 22674130
Int J Cancer. 2008 Sep 1;123(5):1060-7
pubmed: 18546269
Cell. 2010 Jan 22;140(2):268-79
pubmed: 20141840
J Clin Oncol. 2012 Apr 1;30(10):1129-36
pubmed: 22355056
Cell Mol Life Sci. 2006 Sep;63(17):2067-77
pubmed: 16909199
Cancer Lett. 2007 May 8;249(2):133-42
pubmed: 17027147
Semin Roentgenol. 2005 Apr;40(2):90-7
pubmed: 15898407
Cancer Cell. 2012 Jul 10;22(1):21-35
pubmed: 22789536
J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95
pubmed: 18843117
Clin Cancer Res. 2015 Dec 1;21(23):5188-90
pubmed: 26232370
Clin Cancer Res. 2012 Nov 15;18(22):6384-91
pubmed: 23104894
Cancer Res. 2013 May 15;73(10):3145-54
pubmed: 23644530
Cancer Discov. 2012 Oct;2(10):906-21
pubmed: 22777769
J Cell Sci. 2001 Mar;114(Pt 5):853-65
pubmed: 11181169
PLoS One. 2013;8(2):e56505
pubmed: 23457577
Oncogene. 2010 Sep 30;29(39):5392-403
pubmed: 20639906
Oncol Rep. 2013 Jul;30(1):341-9
pubmed: 23677397
Cancer Res. 2002 Jul 15;62(14):4123-31
pubmed: 12124351
Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213
pubmed: 17324579
J Cell Biol. 2010 Feb 22;188(4):595-609
pubmed: 20176926
Clin Cancer Res. 2015 Dec 1;21(23):5253-63
pubmed: 25922429
PLoS One. 2012;7(5):e35231
pubmed: 22567098
EMBO Mol Med. 2014 Apr;6(4):539-50
pubmed: 24500694
Oncogene. 2012 Mar 29;31(13):1683-94
pubmed: 21909141
Cancer Res. 2001 Aug 1;61(15):5736-40
pubmed: 11479209
Oncogene. 2007 Oct 18;26(48):6927-36
pubmed: 17471231
Br J Cancer. 2007 Jul 16;97(2):223-30
pubmed: 17595666
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Cell. 2016 Sep 22;167(1):275-284.e6
pubmed: 27662093
Annu Rev Med. 2007;58:491-504
pubmed: 17052163
J Clin Oncol. 2012 Mar 20;30(9):898-901
pubmed: 22331930
Methods Mol Biol. 2014;1070:1-11
pubmed: 24092428

Auteurs

Asma Boudria (A)

INSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.

Cherine Abou Faycal (C)

INSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.

Tao Jia (T)

INSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.

Stephanie Gout (S)

INSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.

Michelle Keramidas (M)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM, U1209, UMR CNRS 5309, Team Cancer Targets and Experimental Therapeutics, Grenoble, 38042, France.

Chloé Didier (C)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM, U1209, UMR CNRS 5309, Team Cancer Targets and Experimental Therapeutics, Grenoble, 38042, France.

Nicolas Lemaître (N)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Tumor Molecular Pathology and Biomarkers, Grenoble, 38042, France.

Sandra Manet (S)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Cell Adhesion Dynamics and Differentiation, Grenoble, 38042, France.

Jean-Luc Coll (JL)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM, U1209, UMR CNRS 5309, Team Cancer Targets and Experimental Therapeutics, Grenoble, 38042, France.

Anne-Claire Toffart (AC)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Tumor Molecular Pathology and Biomarkers, Grenoble, 38042, France.

Denis Moro-Sibilot (D)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Tumor Molecular Pathology and Biomarkers, Grenoble, 38042, France.

Corinne Albiges-Rizo (C)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Cell Adhesion Dynamics and Differentiation, Grenoble, 38042, France.

Véronique Josserand (V)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM, U1209, UMR CNRS 5309, Team Cancer Targets and Experimental Therapeutics, Grenoble, 38042, France.

Eva Faurobert (E)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Cell Adhesion Dynamics and Differentiation, Grenoble, 38042, France.

Christian Brambilla (C)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Tumor Molecular Pathology and Biomarkers, Grenoble, 38042, France.

Elisabeth Brambilla (E)

Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
INSERM U1209, UMR CNRS 5309, Team Tumor Molecular Pathology and Biomarkers, Grenoble, 38042, France.

Sylvie Gazzeri (S)

INSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.

Beatrice Eymin (B)

INSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France. Beatrice.Eymin@ujf-grenoble.fr.
Université Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France. Beatrice.Eymin@ujf-grenoble.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH